Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (401-410 of 1,211) with videos related to

Pageof 122
Sort By:
JACC. Clinical Electrophysiology|November 24, 2018
Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy PatientsValentina Kutyifa, Annamaria Kosztin, Helmut U Klein, et al.
European Heart Journal|June 24, 2005
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registryKarolina E Szummer, Scott D Solomon, Eric J Velazquez, et al.
European Heart Journal|January 3, 2018
Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fractionViviany R Taqueti, Scott D Solomon, Amil M Shah, et al.
European Heart Journal|September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock, John J V McMurray, Joanna Dobson, et al.
European Heart Journal|April 7, 2009
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)Colin Berry, Karen S Pieper, Harvey D White, et al.
European Heart Journal|June 27, 2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT TrialGeorge V Moukarbel, James E Signorovitch, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.
Circulation. Heart Failure|May 3, 2014
Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunctionAndrew Brenyo, Alon Barsheshet, Valentina Kutyifa, et al.
European Journal of Heart Failure|October 18, 2016
Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trialStephen J Greene, Gregg C Fonarow, Scott D Solomon, et al.
Journal of the American College of Cardiology|December 3, 2016
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart FailureMichael R Zile, Brian L Claggett, Margaret F Prescott, et al.
Pageof 122

Showing results (401-410 of 1,211) with videos related to

Sort By:
Pageof 122
JACC. Clinical Electrophysiology|November 24, 2018
Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy PatientsValentina Kutyifa, Annamaria Kosztin, Helmut U Klein, et al.
European Heart Journal|June 24, 2005
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registryKarolina E Szummer, Scott D Solomon, Eric J Velazquez, et al.
European Heart Journal|January 3, 2018
Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fractionViviany R Taqueti, Scott D Solomon, Amil M Shah, et al.
European Heart Journal|September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programmeStuart J Pocock, John J V McMurray, Joanna Dobson, et al.
European Heart Journal|April 7, 2009
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)Colin Berry, Karen S Pieper, Harvey D White, et al.
European Heart Journal|June 27, 2009
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT TrialGeorge V Moukarbel, James E Signorovitch, Marc A Pfeffer, et al.
Journal of the American College of Cardiology|December 6, 2008
Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) ProgramPeter A Meredith, Jan Ostergren, Inder Anand, et al.
Circulation. Heart Failure|May 3, 2014
Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunctionAndrew Brenyo, Alon Barsheshet, Valentina Kutyifa, et al.
European Journal of Heart Failure|October 18, 2016
Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trialStephen J Greene, Gregg C Fonarow, Scott D Solomon, et al.
Journal of the American College of Cardiology|December 3, 2016
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart FailureMichael R Zile, Brian L Claggett, Margaret F Prescott, et al.
Pageof 122